Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer
| dc.contributor.author | Raissouni, Soundouss | |
| dc.contributor.author | Quraishi, Zarqa | |
| dc.contributor.author | Al-ghamdi, Mohammed | |
| dc.contributor.author | Monzon, Jose | |
| dc.contributor.author | Tang, Patricia | |
| dc.contributor.author | Vickers, Michael M | |
| dc.date.accessioned | 2015-11-23T15:31:18Z | |
| dc.date.available | 2015-11-23T15:31:18Z | |
| dc.date.issued | 2015-10-05 | |
| dc.date.updated | 2015-11-19T13:05:15Z | |
| dc.description.abstract | Abstract Background Regorafenib is a multi-targeted tyrosine kinase inhibitor approved for use in refractory colorectal cancer. We report the first case of seizures secondary to acute liver failure, shortly after initiation of regorafenib in a patient with advanced rectal carcinoma. Case presentation A 64 year-old Caucasian female presented with confusion and generalized tonic–clonic seizures, 5 days after initiation of regorafenib for advanced rectal cancer. Investigations revealed significant elevations in bilirubin and alanine aminotransferase. No other cause for seizures and liver dysfunction were found. After interruption of regorafenib, no further seizures occurred, the symptoms of confusion resolved and liver function returned to normal. Conclusions We report the first case of regorafenib-induced acute liver failure resulting in seizures. We suggest early monitoring for side effects, both clinically and biochemically after initiation of regorafenib. | |
| dc.identifier.citation | BMC Research Notes. 2015 Oct 05;8(1):538 | |
| dc.identifier.uri | http://dx.doi.org/10.1186/s13104-015-1502-4 | |
| dc.identifier.uri | http://hdl.handle.net/10393/33224 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | Raissouni et al. | |
| dc.title | Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer | |
| dc.type | Journal Article |
